A Phase 3 interventional study of 177Lu-edotreotide PRRT and Everolimus in Neuroendocrine Tumors, sponsored by ITM Solucin GmbH. Active, not recruiting at 52 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by ITM Solucin GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Neuroendocrine Tumors with a site in Germany — 6 open to participants now, 10 under way, 4 of them phase 3. Neuroendocrine Tumors · Germany.
Among the 36 studies in Neuroendocrine Tumors with a site in Germany, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2017, is one of 7 in phase 3, and was the 22nd registered.
544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.
Browse Neuroendocrine Tumors studies →6 of the 36 studies in Neuroendocrine Tumors with a site in Germany are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Germany, United States, Brazil and 6 more countries
Ages 18+
Ipsen · Sites in Germany, Austria
Ages 18+
Exelixis · Sites in Germany, United States, Australia and 15 more countries
Ages 18+
Guerbet · Sites in Germany, United States, Brazil and 5 more countries
Ages 18–64
Turning Point Therapeutics, Inc. · Sites in Germany, United States, Australia and 16 more countries
Ages 12+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 9 · Phase 4 4
First in 2001; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 324 is above the median of 41 across 388 interventional studies indexed under Neuroendocrine Tumors.
Median enrollment 160 across the 27 interventional studies, 150 across the 9 observational. Of the 24 that completed or were terminated, 14 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 36 have an industry lead sponsor. The 10 most frequent:
ITM Solucin GmbH is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
ITM Solucin GmbH has 3 studies filed under Neuroendocrine Tumors — fewer than ten, so there is no comparison to draw.
4 of the studies in Neuroendocrine Tumors with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04919226Phase 3ITM Solucin GmbHLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | 2027-06 |
| NCT07087054Phase 3Crinetics Pharmaceuticals Inc.Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | 2027-08 |
| NCT07903532Instituto de Investigación Sanitaria de la Fundación Jiménez DíazMulticenter Study for External Validation of the TB-NET Score | 2027-03 |
| NCT07314164IpsenStudy of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Neuroendocrine Tumors with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
177Lu-edotreotide (177Lu-DOTATOC) A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)
Drug: 177Lu-edotreotide PRRT · Other: Amino-Acid Solution
Everolimus (Afinitor ®) Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)
Drug: Everolimus
PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
Also known as: 177Lu-DOTATOC, 177Lu-Edo
Everolimus will be administered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
Also known as: Afinitor
The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
Also known as: Arginine-Lysine Solution
Progression-Free Survival (PFS)
PFS determined as time elapsed between randomization, and the date of first objective report of tumor progression (evaluated by RECIST criteria v1.1) as evaluated by the Blinded Independent Central Review (BICR), or death.
Time frame: From date of randomization until the date of first documented progression or death, assessed up to 30 months,
Objective Response Rate (ORR)
ORR will be assessed, defined as the proportion of participants achieving partial response (PR) or complete response (CR) as best outcome, after treatment with 177Lu-edotreotide compared to everolimus.
Time frame: Up to 30 months
Overall Survival (OS)
From the date of randomisation until the date of death up to the up to the end of the 5 year post-study follow-up.
Time frame: Overall Survival (OS) will be followed up for 5 years (60 months) after the End of Study (EOS)
The study was conducted in 14 countries. Of the 52 sites that screened at least one participant, 49 sites randomized at least one participant. A total of 324 participants were enrolled in the study. Of these, 309 (95.4%) were randomized in a 2:1 fashion to the 177Lu-edotreotide arm or the control arm. Of the 309 randomized participants, 7 did not receive treatment.
| Milestone | 177Lu-edotreotide PRRT | Everolimus | Non-Randomized Participants of Sub-Study C |
|---|---|---|---|
| Started | 203 | 99 | 14 |
| Safety analysis set (saf) | 203 | 99 | 14 |
| Full analysis set (fas) | 207 | 102 | 0 |
| Completed | 63 | 18 | 4 |
| Not completed | 140 | 81 | 10 |
| Withdrew: Progressive disease | 107 | 53 | 9 |
| Withdrew: Adverse event | 17 | 13 | 0 |
| Withdrew: Protocol violation | 3 | 2 | 0 |
| Withdrew: Non-compliance | 1 | 2 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Death | 7 | 5 | 0 |
| Withdrew: Other (including withdrawal by subject, sponsor request, technical problems) | 5 | 5 | 0 |
| Withdrew: Other: ongoing | 0 | 0 | 1 |
PFS determined as time elapsed between randomization, and the date of first objective report of tumor progression (evaluated by RECIST criteria v1.1) as evaluated by the Blinded Independent Central Review (BICR), or death.
| Months | 177Lu-edotreotide PRRT | Everolimus |
|---|---|---|
| Progression-Free Survival (PFS) | 23.9 (18.7 to 30.0) | 14.1 (9.2 to 20.9) |
ORR will be assessed, defined as the proportion of participants achieving partial response (PR) or complete response (CR) as best outcome, after treatment with 177Lu-edotreotide compared to everolimus.
| Percentage of participants | 177Lu-edotreotide PRRT | Everolimus |
|---|---|---|
| Objective Response Rate (ORR) | 21.9 (16.2 to 27.6) | 4.2 (0.2 to 8.2) |
From the date of randomisation until the date of death up to the up to the end of the 5 year post-study follow-up.
Results for this outcome have not been posted.
Collected over AEs are collected from the signature of the Informed Consent Form (ICF) until the End of Study (EOS), assessed up to approximately 30 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 177Lu-edotreotide PRRT | 14/217 (6.5%) | 66/217 (30.4%) | 204/217 (94%) |
| Everolimus | 7/99 (7.1%) | 44/99 (44.4%) | 98/99 (99%) |
| Event | 177Lu-edotreotide PRRT | Everolimus |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 1/217 | 5/99 |
| Intestinal obstructionGastrointestinal disorders | 2/217 | 3/99 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/217 | 3/99 |
| CholecystitisHepatobiliary disorders | 5/217 | 2/99 |
| Tricuspid valve incompetenceCardiac disorders | 0/217 | 2/99 |
| Disease progressionGeneral disorders | 3/217 | 2/99 |
| PyrexiaGeneral disorders | 0/217 | 2/99 |
| COVID-19Infections and infestations | 2/217 | 2/99 |
| GastroenteritisInfections and infestations | 0/217 | 2/99 |
| PneumoniaInfections and infestations | 1/217 | 2/99 |
| Event | 177Lu-edotreotide PRRT | Everolimus |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 78/217 | 44/99 |
| NauseaGastrointestinal disorders | 79/217 | 21/99 |
| AstheniaGeneral disorders | 65/217 | 36/99 |
| Mucosal inflammationGeneral disorders | 2/217 | 29/99 |
| Oedema peripheralGeneral disorders | 12/217 | 29/99 |
| AnaemiaBlood and lymphatic system disorders | 34/217 | 27/99 |
| StomatitisGastrointestinal disorders | 3/217 | 25/99 |
| FatigueGeneral disorders | 53/217 | 17/99 |
| HyperglycaemiaMetabolism and nutrition disorders | 12/217 | 24/99 |
| RashSkin and subcutaneous tissue disorders | 9/217 | 24/99 |
The baseline demographics are summarized for the Full Analysis Set (FAS), encompassing 309 participants, included all who were randomized to treatment and was used for all efficacy analyses.
| Age, Continuous(Years) | 177Lu-edotreotide PRRT | Everolimus | Total |
|---|---|---|---|
| Mean | 62.8 ± 11.6 | 59.7 ± 12.2 | 61.7 ± 11.9 |
| Sex: Female, Male(Participants) | 177Lu-edotreotide PRRT | Everolimus | Total |
|---|---|---|---|
| Female | 97 | 44 | 141 |
| Male | 110 | 58 | 168 |
| Race/Ethnicity, Customized(Participants) | 177Lu-edotreotide PRRT | Everolimus | Total |
|---|---|---|---|
| Black or African American | 4 | 4 | 8 |
| White | 177 | 84 | 261 |
| Multiple | 0 | 1 | 1 |
| Not Reported | 26 | 13 | 39 |
| Race/Ethnicity, Customized(Participants) | 177Lu-edotreotide PRRT | Everolimus | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 9 | 15 |
| Not Hispanic or Latino | 193 | 89 | 282 |
| Unknown or Not Reported | 8 | 4 | 12 |
| Weight(Kg) | 177Lu-edotreotide PRRT | Everolimus | Total |
|---|---|---|---|
| Mean | 73.70 ± 15.14 | 74.13 ± 15.72 | 73.84 ± 15.30 |
| BMI (Body Mass Index)(Kg/m2) | 177Lu-edotreotide PRRT | Everolimus | Total |
|---|---|---|---|
| Mean | 25.59 ± 4.48 | 25.32 ± 4.50 | 25.51 ± 4.48 |
| Height(cm) | 177Lu-edotreotide PRRT | Everolimus | Total |
|---|---|---|---|
| Mean | 169.47 ± 9.59 | 170.80 ± 9.80 | 169.89 ± 9.66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Nov 2024, 93 months.
Results were first posted in Apr 2026, 1 year 4 months after primary completion.
Of 25 phase 3 interventional studies under Neuroendocrine Tumors, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 85. This study's 93 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 177Lu-octreotide, DOTA(0)-Tyr(3)-
ITM Solucin GmbH